Blaine Penny
CEO | Lumiio
Calgary, AB, CANADA
Blaine Penny has over 20 years of experience in the health, technology, and engineering sectors.
Biography
Blaine began his career as a Professional Engineer, with a focus on leadership and management roles. He has over 20 years of experience in the health, technology, and engineering sectors leading and managing large teams and portfolios, capital investment projects, product management, M&A, and go-to-market strategies. Fifteen of those years were in Executive roles and included Co-founder and CEO of MitoCanada, CEO of the start-up engineering firm Integrated Sustainability, and Vice President of the global technology firm IHS Markit.
Blaine’s involvement in rare disease advocacy and research began in 2008 with the tragic onset of a mitochondrial disease in his then 4-year-old son. Motivated to help others going through similar experiences, Blaine co-founded the MitoCanada Foundation, which has raised over $3 million to advance mitochondrial medicine.
Blaine’s governance experience includes serving on multiple Boards. He is currently a Director with the MitoCanada Foundation and Caltaf. Additionally, Blaine is an Executive Advisor to the Mitochondrial Innovation Initiative (Mito2i) – a strategic initiative at the University of Toronto and was a former Director with the Canadian Organization for Rare Disorders (CORD).
Industry Expertise (3)
Investment Management
Health and Wellness
Energy
Areas of Expertise (6)
Go-To-Market Strategies
Capital Investments
Rare Diseases
Product Management
Mitochondrial Diseases
Engineering
Education (1)
Lakehead University: B.Eng., Civil Engineering 1999
Multimedia
Publications:
Documents:
Photos:
Videos:
Audio/Podcasts:
Links (1)
Selected Media Appearances (1)
Global Digital Health Company Celebrates Continued Growth with Rebrand to New Name Lumiio
Business Wire online
2021-08-17
"The rebrand and refreshed strategic vision are critical steps to the future growth and trajectory of Lumiio," said Blaine Penny, CEO. "We will continue to be driven to illuminate the way towards a future of personalized and predictive medicine for patient communities.”
Social